The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with <i>KRAS</i> G12C Inhibitors in Preclinical Models
Nathan M. Jameson(Tracon Pharmaceuticals (United States)), Mark R. Lackner(Tracon Pharmaceuticals (United States))
Cited by 6
Related Papers
Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
|Molecular Cancer Therapeutics|2025|6